Dual branding is a pharmaceutical industry strategy where the same active ingredient is marketed under different brand names. This strategy is often applied across indications, markets, or formulations, especially in biologics, rare diseases, and settings with varied access dynamics.

While dual branding can be part of a commercial strategy, it is sometimes required by regulators to ensure clear differentiation between products.

This is particularly relevant when the same molecule is used for distinct indications, patient populations, or reimbursement pathways.

This article focuses on cases where dual branding is a regulatory requirement in Europe, with a special focus on rare diseases and oncology. It also discusses the strategic benefits that can arise when regulatory-driven dual branding is aligned with thoughtful brand planning.

Dual Branding Use Cases

In Europe, dual branding is not only a strategic option but, in certain cases, a regulatory requirement: 

• When a new marketing authorization is submitted for a different therapeutic indication
• When the originally proposed brand name is rejected, cancelled, or objected to by a European Union (EU) Member State during the name review process
• When there are verifiable public health reasons or a co-marketing agreement with an independent partner, as outlined in Article 82(1) of Regulation (EC) No 726/2004
• When the same active pharmaceutical ingredient has orphan and non-orphan indications, the indications must be marketed under distinct brand names, necessitating a dual branding approach

Growth Opportunities in Dual Branding

In rare diseases and oncology, where access pathways are complex and patient populations distinct, regulatory-driven dual branding can become a growth lever. This potential can be unlocked when the approach is strategically planned and executed to align regulatory compliance with brand and market objectives.

Securing/Preserving Orphan Drug Designation and Market Exclusivity

For pharmaceutical companies operating in rare diseases and rare cancers, dual branding offers a way to expand therapeutic reach while preserving certain access advantages. When a non-orphan drug is approved for a new rare indication, the introduction of a second brand allows companies to secure an orphan drug designation and benefit from associated opportunities. 

Tailoring Brands to Distinct Patient Populations

If an orphan drug is extended to a broader, non-orphan population, a new brand helps preserve the exclusivity and strategic positioning of the original product. This flexibility is not available through simple indication extensions under a single brand name.

Moreover, dual branding enables companies to better meet the needs of distinct patient populations. With separate brands, they can develop tailored value communications, education and support programs that reflect the unique clinical context of each indication. This differentiation not only improves the patient and prescriber experience but also strengthens the clarity and value proposition of each product in the marketplace

Driving Market Access and Revenue Optimization

From a commercial and market access perspective, the advantages of dual branding are particularly significant in the context of rare diseases. It supports the retention or acquisition of orphan drug designation and the exclusivity it brings, while enabling companies to expand their presence into adjacent markets. The use of different brands allows for distinct pricing and reimbursement strategies, helping companies avoid price erosion and align with the expectations of various payers and health technology assessment bodies. It also offers flexibility in sequencing health technology assessment submissions and managing market entry.

Conclusion

While dual branding introduces operational complexity and risks, such as brand cannibalization or prescriber confusion, it offers significant advantages. The risks can be mitigated through clear product differentiation and internal alignment. When executed strategically, dual branding not only satisfies regulatory demands but also unlocks commercial growth, strengthens market presence in rare diseases, and ultimately benefits patients through more targeted care.